WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year
SHANGHAI, July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been named as a constituent company of the FTSE4Good Index Series. This marks the fourth consecutive year the company has been included in the Index for its outstanding sustainability performance. WuXi Biologics Named...
3D Artificial Cornea from Stem Cells: Chula Researchers Advance Canine Corneal Wound Treatment
BANGKOK, July 10, 2024 /PRNewswire/ -- Chulalongkorn University's Faculty of Veterinary Science and the Faculty of Engineering have worked together to research and develop a three-dimensional artificial cornea from stem cells that offers a way to treat deep corneal wounds in dogs. The innovation helps to solve the problem of treatment methods that rely on tissue replacement which is...
KOSÉ, I Peace, and Reju Enter Strategic Partnership to Develop Personalized Beauty Products Based on iPS Cells
Demonstration testing of "my own" beauty products PALO ALTO, Calif., July 9, 2024 /PRNewswire/ -- KOSÉ Corporation (Headquarters: Chuo-ku, Tokyo; President: Kazutoshi Kobayashi), I Peace, Inc. (Headquarters: Palo Alto, California, USA; Founder & CEO: Koji Tanabe), and Reju, Inc. (Headquarters: Minato-ku, Tokyo; CEO: Yurie Kamiya) have agreed to enter a strategic...
Bestqool Pro Series Redefines the Standard of Red Light Therapy Devices: Cutting-Edge Technology Undergone the Third-party Laboratory Diagnostic Testing
NEW YORK, July 9, 2024 /PRNewswire/ -- Bestqool, as one of the industry's top makers of innovative red light therapy devices for over six years, in recent months proactively sent their Pro Series devices to LightLab International Allentown LLC, a reputable third-party laboratory in the US. Bestqool emphasizes the authenticity and reliability of its devices and has acquired a place...
Clinion Applauded by Frost & Sullivan for Enabling Interoperability and Continuity in Clinical Trials Management with its eClinical Solutions
Clinion's decentralized clinical trials and innovative eClinical platform enhance accessibility, cost efficiency, ease of use, regulatory compliance, and sustainability in clinical development. SAN ANTONIO, July 9, 2024 /PRNewswire/ -- Frost & Sullivan recently assessed the integrated clinical trial optimization industry and, based on its findings, recognizes Clinion with the 2024 North American Technology Innovation...
Pulnovo Medical Announces Joining PHA’s (Pulmonary Hypertension Association) Corporate Committee
SHANGHAI, July 9, 2024 /PRNewswire/ -- Pulnovo Medical, a globally recognized device pioneer in the treatment for pulmonary hypertension and heart failure, has recently announced its partnership with the Pulmonary Hypertension Association (PHA). This partnership not only underscores Pulnovo Medical's growing global influence but also empowers PHA's mission to extend and improve the lives of those affected by pulmonary...
【C.S】Cordyceps Sunshine Successfully Secures DTC Eligibility
TAIPEI, July 9, 2024 /PRNewswire/ -- Cordyceps Sunshine【C.S】Group is a leading expert in Taiwan's precious fungal field. Since 2020, the company has secured multiple patented cultivation techniques for the most representative medicinal fungus in Taiwan, Taiwanofungus camphoratus. C.S Group has successfully established and mass-produced cultivation centers in Yilan, Taiwan, and Guangdong, China. We are pleased to announce that the company...
Goodix Launches Its Latest Automotive-Grade Bluetooth LE SoC and CGM Solutions at electronica China 2024
SHENZHEN, China, July 8, 2024 /PRNewswire/ -- Goodix Technology today unveiled its Continuous Glucose Monitoring (CGM) solutions and automotive-grade Bluetooth LE SoC at the electronica China 2024. Demonstrating a dedication to innovation in sensing and wireless technology, Goodix showcased its latest offerings and commercial accomplishments, further driving the adoption of emerging applications in the healthcare and automotive electronics sectors....
Porton J-STAR and Enabling Technologies Consortium Collaboration on Co-processing Platform Technology Development
CHONGQING, China, July 8, 2024 /PRNewswire/ -- Porton J-STAR today announced that Enabling Technologies Consortium (ETC) has awarded a two-year contract to J-STAR to collaborate on "Co-processing Platform Technology." The primary goal of co-processing is to improve the reliability and efficiency of drug product manufacturing processes to support direct compression or continuous manufacturing techniques. Co-processed APIs...
Alteogen Receives Ministry of Food and Drug Safety (MFDS) Approval for Tergase®
Tergase® poised to capture a fair share of the global hyaluronidase market. DAEJEON, South Korea, July 8, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced that the Ministry of Food and Drug Safety (MFDS) of Korea approved its New Drug Application (NDA) for Tergase® (recombinant hyaluronidase). Tergase® is a recombinant human hyaluronidase developed utilizing Alteogen's proprietary Hybrozyme™ Technology. Dermal...
